Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

SUPN – Supernus Pharmaceuticals Inc

Float Short %

9.6

Margin Of Safety %

-11

Put/Call OI Ratio

0.18

EPS Next Q Diff

-0.17

EPS Last/This Y

0.92

EPS This/Next Y

0.16

Price

44.88

Target Price

43

Analyst Recom

1.8

Performance Q

40.07

Relative Volume

1.33

Beta

0.76

Ticker: SUPN




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25SUPN33.60.160.00497
2025-07-28SUPN33.40.150.27508
2025-07-29SUPN33.450.150.27508
2025-07-30SUPN33.590.160.00521
2025-07-31SUPN35.10.154.39536
2025-08-01SUPN35.50.350.00658
2025-08-04SUPN37.070.350.08663
2025-08-05SUPN37.490.360.05660
2025-08-06SUPN42.490.3310.76709
2025-08-07SUPN41.461.7847.291618
2025-08-08SUPN41.262.3373.001953
2025-08-11SUPN40.542.92972.002301
2025-08-12SUPN41.244.550.003262
2025-08-13SUPN42.624.530.063264
2025-08-14SUPN42.164.192.003319
2025-08-15SUPN42.694.1858.823318
2025-08-18SUPN42.990.190.13717
2025-08-19SUPN41.990.190.13717
2025-08-20SUPN42.690.190.40725
2025-08-21SUPN43.340.200.08732
2025-08-22SUPN44.860.180.04809
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25SUPN33.58-30.4- 1.97
2025-07-28SUPN33.50-30.4- 1.97
2025-07-29SUPN33.45-30.4- 1.97
2025-07-30SUPN33.56-30.4- 1.97
2025-07-31SUPN35.10-30.4- 1.97
2025-08-01SUPN35.51-30.4- 1.97
2025-08-04SUPN37.05-30.4- 1.97
2025-08-05SUPN37.53-30.4- 1.97
2025-08-06SUPN42.46-30.4- 1.97
2025-08-07SUPN41.46-30.4- 1.97
2025-08-08SUPN41.23-30.4- 2.31
2025-08-11SUPN40.58-69.0- 2.25
2025-08-12SUPN41.26-72.6- 2.25
2025-08-13SUPN42.64-72.6- 2.25
2025-08-14SUPN42.15-72.6- 2.25
2025-08-15SUPN42.69-72.6- 2.25
2025-08-18SUPN42.98-72.6- 2.25
2025-08-19SUPN42.00-72.6- 2.25
2025-08-20SUPN42.70-72.6- 2.25
2025-08-21SUPN43.35-72.6- 2.25
2025-08-22SUPN44.88-72.6- 2.25
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25SUPN-0.48-0.559.59
2025-07-28SUPN-0.48-1.009.59
2025-07-29SUPN-0.48-1.009.59
2025-07-30SUPN-0.37-1.009.59
2025-07-31SUPN-0.37-1.009.59
2025-08-01SUPN-0.37-1.009.59
2025-08-04SUPN-0.37-0.719.59
2025-08-05SUPN-0.37-0.719.59
2025-08-06SUPN-0.03-0.719.59
2025-08-07SUPN-0.03-0.719.59
2025-08-08SUPN-4.74-0.719.58
2025-08-11SUPN-4.74-0.809.58
2025-08-12SUPN-4.74-0.809.54
2025-08-13SUPN-4.74-0.809.54
2025-08-14SUPN-4.64-0.809.55
2025-08-15SUPN-4.64-0.809.55
2025-08-18SUPN-4.88-2.329.55
2025-08-19SUPN-5.05-2.329.60
2025-08-20SUPN-4.62-2.329.60
2025-08-21SUPN-4.62-2.329.60
2025-08-22SUPN-4.62-2.329.60
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

0.78

Avg. EPS Est. Current Quarter

0.3

Avg. EPS Est. Next Quarter

0.61

Insider Transactions

-4.62

Institutional Transactions

-2.32

Beta

0.76

Average Sales Estimate Current Quarter

175

Average Sales Estimate Next Quarter

197

Fair Value

39.94

Quality Score

68

Growth Score

89

Sentiment Score

86

Actual DrawDown %

-2.6

Max Drawdown 5-Year %

-45.9

Target Price

43

P/E

39.22

Forward P/E

18.6

PEG

8.12

P/S

3.78

P/B

2.37

P/Free Cash Flow

13.54

EPS

1.14

Average EPS Est. Cur. Y​

2.25

EPS Next Y. (Est.)

2.42

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

9.7

Relative Volume

1.33

Return on Equity vs Sector %

-18.6

Return on Equity vs Industry %

-1.8

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.26

EBIT Estimation

Supernus Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 674
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
stock quote shares SUPN – Supernus Pharmaceuticals Inc Stock Price stock today
news today SUPN – Supernus Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch SUPN – Supernus Pharmaceuticals Inc yahoo finance google finance
stock history SUPN – Supernus Pharmaceuticals Inc invest stock market
stock prices SUPN premarket after hours
ticker SUPN fair value insiders trading